, Volume 71, Issue 3, pp 263-271
Date: 18 Nov 2012

Drugs in Development for Viral Hepatitis

Rent the article at a discount

Rent now

* Final gross prices may vary according to local VAT.

Get Access
This is an excerpt from the content

The approval of the first direct-acting antiviral (DAA) drugs for treatment of hepatitis C virus (HCV) is anticipated in 2011. Due to the promise that these compounds, telaprevir and boceprevir, may improve sustained viral response (SVR) rates up to 75% in treatment-naïve or relapse genotype 1 (G1) patients, there will likely be widespread use of these drugs in the US and EU. Unfortunately, this also creates the potential for misuse of these new drugs for multiple reasons such as poor understanding of treatment populations, inadequate viral assay testing, poor adverse effect management and lack of monitoring for antiviral resistance. In an effort to avoid the casual or incorrect use of these new medications, the American Association for The Study of Liver Diseases (AASLD) introduced a new programme to their 2010 meeting, the Viral Hepatitis Debrief. The purpose of the debrief is to move the field forward by immediately synthesizing new data from the annual meeting into a reasonable set